Galapagos traded at 39.85 this Wednesday February 1st, decreasing 0.54 or 1.34 percent since the previous trading session. Looking back, over the last four weeks, Galapagos lost 3.53 percent. Over the last 12 months, its price fell by 31.94 percent. Looking ahead, we forecast Galapagos to be priced at 39.56 by the end of this quarter and at 36.04 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
39.85
Daily Change
-1.34%
Yearly
-31.94%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
argenx SE 344.90 -2.10 -0.61% 42.23%
AstraZeneca 10,280.00 -310.00 -2.93% 19.79%
Biogen 291.60 0.70 0.24% 29.62%
Genmab 2,658.00 -14.00 -0.52% 15.16%
Gilead Sciences 84.00 0.06 0.07% 27.62%
GRIFOLS 12.14 0.02 0.12% -22.68%
GlaxoSmithKline 1,419.60 -3.80 -0.27% -13.96%
Hikma Pharmaceutical 1,692.50 -16.00 -0.94% -17.16%
Incyte Corp 85.60 0.46 0.54% 15.07%
Merck 182.50 -8.55 -4.48% -7.87%
Neurocrine Biosciences 110.22 -0.71 -0.64% 39.96%
Novartis 80.22 -2.24 -2.72% 2.04%
Roche Holding 279.40 -5.85 -2.05% -21.76%
Sanofi 88.70 -0.97 -1.08% -3.88%
UCB 73.80 -1.58 -2.10% -16.00%
Vertex Pharmaceuticals 317.27 -5.83 -1.80% 30.16%

Indexes Price Day Year
NL25 748 2.49 0.33% -2.34%
BE20 3855 -5.07 -0.13% -6.49%
EU100 1328 0.50 0.04% -0.70%

Galapagos
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.